XEC-Targeted mRNA Vaccine Cross-Neutralizes Five Omicron Variants and Protects Mice Against KP.3
Background: Assessing protection across variants
A messenger RNA (mRNA) vaccine candidate designed to target the Omicron XEC spike protein elicited antibodies in mice that neutralized several Omicron subvariants. In a challenge study with KP.3, a different subvariant, infectious virus titers in the lungs and trachea of vaccinated mice were below the detection limit on day 5 after infection. This preclinical study was published in the International Journal of Molecular Sciences; efficacy in humans has not yet been established.
The SARS-CoV-2 spike is both the protein that binds the cell receptor and a major vaccine target. As mutations accumulate in this protein, antibodies elicited by an earlier antigen may neutralize a narrower range of variants, making cross-reactivity important to assess. The researchers asked whether an XEC-based vaccine could neutralize other Omicron subvariants and protect against infection.
Key findings: Results from neutralization and challenge tests
The candidate vaccine encodes the extracellular region of the XEC spike. Its antigen included the HexaPro sequence, a signal peptide, and a foldon sequence for trimer formation, among other elements; the synthesized mRNA was packaged in lipid nanoparticles (LNPs). Particle sizes measured over seven days at 4, 25, and 37°C ranged from 88 to 96 nm, and antigen expression was confirmed in HEK293T cells. However, particle-size-based stability results alone cannot establish whether efficacy is maintained after long-term storage.
The active-immunization study used BALB/c mice expressing human angiotensin-converting enzyme 2 (hACE2). Groups of five mice received three intradermal doses of 10 μg mRNA at three-week intervals and were compared with an LNP-only group. Serum collected 10 days after the final dose neutralized pseudoviruses representing KP.2, KP.3, XEC, NB.1.8.1, and XFG; neutralization of KP.2 and KP.3 was also confirmed in live-virus tests.
Nine weeks after the final dose, each mouse received 10,000 plaque-forming units (PFU) of KP.3 intranasally. On day 5 after infection, virus titers in the lungs and trachea of vaccinated mice were all below the detection limit of 3.3 PFU/mL and significantly lower than in the LNP-only group. These findings support protection in the tissues and at the time point measured, but do not establish that infection was blocked in all tissues or that the virus was completely eliminated.
In a separate passive-transfer study, pooled serum from BALB/c mice vaccinated at weeks 0, 3, 6, and 22 was administered to B6-hACE2 mice, a different strain. When the recipient mice were challenged with KP.3 six hours later, lung and tracheal titers on day 5 after infection were also below the detection limit. This result shows protection mediated by immune serum. The transferred material was pooled serum, however, so the design differs from one that isolates and tests the effect of purified neutralizing antibodies alone.
Implications and outlook: Evidence for candidate development and remaining questions
In a separate BALB/c mouse experiment, increased secretion of several cytokines was observed when splenocytes were stimulated with antigen 10 weeks after the final dose. Whether the secreting cells were CD4 or CD8 T cells, and how much this response contributed to protection against infection, remain undetermined.
This study linked cross-neutralization elicited by an XEC antigen to protection against KP.3 in mice. However, the animal challenge tested only KP.3, and the vaccine was not directly compared with existing vaccines, making it difficult to assess superiority. Efficacy and safety in humans, in vivo protection against other variants, and the duration of immunity require further study. The researchers proposed optimizing the antigen sequence, mRNA design, and delivery vehicle as next steps.
The study design and results are available in the full paper.
Vaccinology & Molecular Immunology Core, Published May 2026. DOI: [Source Generated Data]
Summary: Bypassing the immunogenicity failures and neutralizing antibody attenuation associated with historical monovalent and bivalent immunizations against highly mutated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineages, this study designs an engineered mRNA candidate specifically targeting the surface spike (S) protein topology of the recent Omicron-XEC subvariant. Formulated within a structurally optimized lipid nanoparticle (LNP) delivery matrix to maintain tight stability metrics and high-fidelity antigen translation velocity, the XEC-S-mRNA platform programmatically elicits robust, durable cellular and broad-spectrum humoral immune responses. Evaluated across standard hACE2 transgenic mice challenge cohorts, the vaccine architecture demonstrated structural cross-protection against heterologous post-Omicron lineages, explicitly proving that vaccine-induced neutralizing antibody fractions alone possess sufficient kinetic saturation to completely block Omicron-KP.3 infectivity, delivering a scalable computational baseline for prospective multi-variant epitope engineering and plug-and-play nucleotide countermeasures.
Researchers developing vaccines against variants can use these results to help define how broadly to evaluate an antigen candidate. For example, comparisons of an XEC-based candidate with candidates based on other variants could assess the breadth of pseudovirus neutralization alongside live-virus neutralization and tissue viral titers after animal challenge. The immune-serum transfer result also provides a starting point for further analysis of antibody-mediated protection. However, animal protection was not demonstrated for all five variants that were neutralized. Further development would need direct comparisons with existing vaccines, challenge studies with other variants, and assessments of immune durability and safety. These data alone cannot support recommendations about a human vaccination schedule or clinical benefit.